Treatment
Intravenous immunoglobulin clinical trials
We’re tracking 23 recruiting studies that include Intravenous immunoglobulin, each written for real people, not researchers, below.
Recruiting studies
- NCT07202052RecruitingPhase 2/Phase 3
Antibiotics or immunoglobulin for infections in blood cancer
This trial compares two treatments—antibiotics or immunoglobulin (a blood product with infection-fighting antibodies)—to see which better prevents infections in people with certain blood cancers like CLL, multiple myeloma, or non-Hodgkin's lymphoma.
Adelaide, South AustraliaAges 18 years+ - NCT06533098RecruitingPhase 3
Nipocalimab vs IVIG for FNAIT in pregnancy
This study tests a new medicine called nipocalimab compared to standard IVIG treatment for pregnant women who are at risk of a serious condition where the mother's antibodies attack the baby's platelets (FNAIT). The goal is to see if nipocalimab can prevent complications like bleeding in the baby.
Birmingham, AlabamaAges 18–45 - NCT04656184RecruitingPhase 3
Anakinra vs IVIG for kids who don’t respond to first IVIG
This study compares two treatments—anakinra and IVIG—for children with Kawasaki disease who still have fever after their first standard IVIG treatment. It aims to find which option works better and is safer for “IVIG non-responders” who may be at risk for heart complications.
Le Kremlin-Bicêtre, Val De MarneAges 3 months–17 years - NCT07299695RecruitingPhase 3
IVIG for sudden worsening of IPF
This trial tests whether giving a medication called intravenous immunoglobulin (IVIG) can help people with IPF who are hospitalized for a sudden worsening of their lung condition. The treatment aims to reduce inflammation and improve recovery.
PátraiAges 18 years+ - NCT07233213RecruitingPhase 3
IVIG for chronic low platelet condition
This trial tests an intravenous immunoglobulin (IVIG) treatment for chronic immune thrombocytopenia (ITP), a condition where the immune system attacks platelets, causing low counts and bleeding risk. It aims to safely raise platelet levels using donated antibodies.
Ankara, AltındağAges 18–65 - NCT06954441RecruitingPhase 3
A new immune therapy for people with low IgG
This trial tests a new immunoglobulin treatment (V-Immune) for people with primary IgG deficiency who are already on IVIG therapy. It aims to see if this new therapy can effectively replace their current treatment.
Recife, PernanbucoAges 2 years+ - NCT06373211RecruitingPhase 2
Early immunotherapy for nerve damage linked to anti-Hu antibodies
This trial tests whether a combination of three immune-suppressing drugs (IVIg, cyclophosphamide, and methylprednisolone) given early can improve balance and sensation in people with a rare nerve condition caused by anti-Hu antibodies. The goal is to stop or slow the nerve damage before it gets worse.
ParisAges 18 years+ - NCT06290141RecruitingPhase 3
Testing riliprubart vs. standard IVIg for CIDP
This trial tests whether a new medication called riliprubart works as well as the usual IVIg treatment for people with chronic inflammatory demyelinating polyneuropathy (CIDP). It may offer another option for managing your condition.
Homewood, AlabamaAges 18 years+ - NCT03630211RecruitingPhase 2
Study of stem cell transplant for systemic sclerosis in youth
This Phase 2 study tests whether an “autologous” stem cell transplant—using your own stem cells—can reduce systemic sclerosis disease activity. It is mainly for children, teens, and young adults whose disease did not improve despite standard medicines.
Pittsburgh, PennsylvaniaAges 8–60 - NCT05520892RecruitingPhase 4
IVIG dose options for newly diagnosed childhood ITP
This study compares two intravenous (IV) IgG treatment regimens for children newly diagnosed with immune thrombocytopenia (ITP). It aims to find a regimen that works well and is safe for raising low platelet counts.
Fuzhou, FujianAges 4 weeks–14 years - NCT07561125RecruitingPhase 2
IVIG for lung disease in very preterm infants
This trial tests whether giving intravenous immunoglobulin (IVIG) early after birth can help prevent or treat a serious lung condition called bronchopulmonary dysplasia (BPD) in babies born at 28 weeks or earlier. It may help reduce the need for breathing support and oxygen.
ShanghaiAges 1 day–2 months - NCT04968899RecruitingPhase 3
IgG IV plus prednisone versus high-dose dexamethasone for ITP
This Phase 3 study compares two ways of treating immune thrombocytopenia (ITP) to raise blood platelet counts and reduce bleeding. It tests whether IgG given through a vein plus prednisone works better (or safer) than high-dose dexamethasone.
CréteilAges 18–80 - NCT05325008RecruitingPhase 3
IVIG treatment for BK virus after kidney transplant
This Phase 3 trial tests IVIG (an antibody medicine given through a vein) to treat BK virus infection after kidney or pancreas-kidney transplant. It may help lower the BK virus in the blood and protect the transplanted kidney.
Canberra, Australian Capital TerritoryAges 2 years+ - NCT06925360RecruitingPhase 2
IVIG for lung disease in premature babies
This trial tests if intravenous immunoglobulin (IVIG) can help prevent or treat bronchopulmonary dysplasia (BPD), a lung condition in premature babies. It is for very preterm infants born between 25 and 29 weeks who show early signs of BPD and are enrolled in the first day of life.
Shanghai, Shanghai MunicipalityAges Up to 2 months - NCT06158854RecruitingPhase 1/Phase 2
Study of etentamig (ABBV-383) for AL amyloidosis
This study tests a new drug called etentamig (ABBV-383) given through a vein to see if it can control disease activity in people with AL amyloidosis who have already tried other treatments. It may help if your disease has progressed or is not responding well to prior therapies.
Miami, FloridaAges 18 years+ - NCT07059000RecruitingPhase 3
Study of a drug for adults with chronic ITP
This trial tests an intravenous immunoglobulin (IVIg) treatment for adults who have had chronic immune thrombocytopenia (ITP) for more than a year. The goal is to see if this treatment can safely raise your platelet count.
Los Angeles, CaliforniaAges 18–70 - NCT06599697RecruitingPhase 2
IVIG for anti-HMGCR muscle disease
This trial tests if IVIG (intravenous immunoglobulin, a donated blood product that helps the immune system) can improve muscle strength and reduce damage in people with anti-HMGCR immune-mediated necrotizing myopathy (a rare muscle disease where the immune system attacks muscle cells). It may help you if your muscle weakness is not too severe and you haven't tried IVIG before.
Birmingham, AlabamaAges 16 years+ - NCT05584631RecruitingPhase 1
Switching IVIG to weekly SCIG for CIDP treatment
This Phase 1 study compares IVIG given through an IV versus SCIG given under the skin, for people with CIDP. It aims to find the right weekly SCIG dose based on your current IVIG dose, which could make treatment more convenient.
New Brunswick, New JerseyAges 18–65 - NCT07202065RecruitingPhase 2/Phase 3
Preventing infections with antibiotics or immunoglobulin in blood disorders
This study looks at whether a different dose of IVIg (antibody treatment through the vein) or adding antibiotics can help prevent infections in people with low antibody levels. It's for patients already on steady IVIg who cannot safely stop it.
Adelaide, South AustraliaAges 18 years+ - NCT07202078RecruitingPhase 2/Phase 3
Starting immunoglobulin for infection prevention in hematology
This trial tests whether giving immunoglobulin to adults with low antibody levels can prevent infections. It aims to compare immunoglobulin with antibiotic therapy or no added treatment for people with blood conditions.
Adelaide, South AustraliaAges 18 years+ - NCT06989541Recruiting
Immunoglobulin for low antibodies after CAR T-cell therapy
This trial tests whether giving immunoglobulin (a treatment that boosts your antibodies) can help people who developed very low antibody levels after CAR T-cell therapy for cancer. It may help prevent infections and improve recovery.
Edmonton, AlbertaAges 18 years+ - NCT07202091RecruitingPhase 2/Phase 3
Stopping or extending immunoglobulin therapy to prevent infections
This trial tests whether it is safe to stop or extend immunoglobulin (Ig) therapy for people with low antibody levels, or if switching to preventive antibiotics works just as well to prevent infections.
Adelaide, South AustraliaAges 18 years+ - NCT06958796RecruitingPhase 4
CMV immunoglobulin to prevent disease after transplant
This trial tests whether giving CMV immunoglobulin (an antibody medicine) after transplant can help prevent a serious CMV infection in people who receive a kidney or liver from a CMV-positive donor. You might be eligible if you are getting one of these transplants and are at high risk for CMV.
Boston, MassachusettsAges 18–75
What Intravenous immunoglobulin is being studied for
Conditions with recruiting Intravenous immunoglobulin studies.
Common questions
- Are there clinical trials studying Intravenous immunoglobulin?
- Yes. Clin2 currently lists 23 recruiting studies that include Intravenous immunoglobulin, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Intravenous immunoglobulin trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Intravenous immunoglobulin an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Intravenous immunoglobulin or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.